NeuroPace Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
35.8%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$0.56next fiscal year
Monitoring Framework
Key Performance Indicators
RNS System Revenue Quarterly21.7MTarget: 21% to 23% underlying RNS growth for FY 2026
Total Revenue (Continuing Operations) Quarterly22.1MTarget: $99 million to $101 million for FY 2026
Non-GAAP Gross Margin (Excluding DIXI Medical) Quarterly8,250.0%Target: 81.5% to 82.5% for FY 2026
Watch Items
- FDA Approval of NAUTILUS PMA Supplement for Idiopathic Generalized Epilepsy (IGE)Trigger: PMA Supplement approval expected in mid-2026Action: Monitor regulatory announcements and subsequent commercial launch preparation
- Discontinued Operations Reporting of DIXI MedicalTrigger: Transition to discontinued operations starting in Q2 2026 financial resultsAction: Adjust financial models to evaluate core RNS business performance on a continuing operations basis
- Adoption and Integration of AI-Driven ECoG AssistantTrigger: FDA approval announced in late May 2026Action: Track physician adoption rates and clinical workflow efficiency improvements
Research as of 19 Jun 2026